Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors
Conclusions:
Long-term abiraterone treatment was well tolerated in mCRPC patients with controlled cardiovascular comorbidities/risk factors, with no apparent worsening of cardiovascular conditions from baseline over an extended observation period.
Source: Therapeutic Advances in Medical Oncology - Category: Cancer & Oncology Authors: Verzoni, E., Grassi, P., Ratta, R., Niger, M., De Braud, F., Valdagni, R., Procopio, G. Tags: Original Research Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Electrocardiogram | Endocrinology | Heart | Hypertension | Prednisone | Prostate Cancer | Stroke